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ABSTRACT 
 Cancer is the second leading cause of mortality in the United States 
today, and equally prevalent throughout the world. Traditional treatments such as 
chemotherapy and radiotherapy have thus far proven unable to treat the disease 
with high efficacy, with different cancer types often requiring different treatments 
providing a spectrum of results. Cancer types in the late stages often have no 
adequate treatment at all. Over the past two decades, research in the field of 
gene therapy has created new hope in finding a remedy for cancer that displays 
a high efficacy in treating many different types and stages. The p53 tumor 
suppressor gene has garnered a great deal of interest, as p53 mutation or 
inactivation is present in approximately 50% of all cancers. The loss of p53 
activity can be attributed to several different causes, including mutation of the 
p53 gene or overexpression of p53 inhibitors. Research has illustrated that the 
p53 protein plays an important role in tumor suppression by inducing 
senescence, cell cycle arrest, or cell apoptosis. Studies have shown that 
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reactivation of p53 in tumor cells leads to tumor cell apoptosis and overall tumor 
regression. The focus of p53 research has now shifted to strategies of 
reintroducing or reactivating the gene in tumor cells so that it may carry out its 
anti-tumor functions. Of the strategies proposed, the use of adenovirus to 
introduce p53 shows the most promise. Adenoviruses bind to and enter the cell, 
and, after escaping proteasomal degradation, travel to the nucleus where they 
inject their genetic material. By delivering wild-type p53 gene into tumor cells 
using adenovirus, large amounts of p53 protein are transcribed in the cell and 
initiate its antitumor properties. Many clinical trials using adenovirus-mediated 
p53 gene transfer (Ad-p53) have been performed with generally positive results 
across a variety of cancer types. Ad-p53 in combination with more traditional 
treatments like chemotherapy and radiotherapy has been especially promising. 
The engineering of both adenoviral vectors and the p53 gene to be delivered 
presents new options for further increasing the efficacy of this therapeutic 
approach. Both Onyx-015, a selectively replicating adenovirus, and Ad-p53vp, a 
p53 gene that avoids inhibition, have been used in clinical trials with success. As 
a whole the field of adenovirus-mediate p53 gene transfer is promising and holds 
many advantages to classical treatments, but is still in the early stages of 
research. Further research must be completed so this therapy may be widely 
approved and used. The specific combination of Ad-p53 and traditional therapies 
has proven highly effective and should be used in clinical settings immediately. 
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III. INTRODUCTION 
 A. Cancer History  
 Throughout history societies have attempted to understand and find a cure 
for what we now describe as cancer. Hippocrates initially hypothesized cancer 
was caused by an excess of black bile, one of the four humors believed to be 
present in the human body. Later theories would blame an excess of lymph fluid, 
chronic irritation, and trauma.  In Holland in the seventeenth century, doctors 
Zacutus Lusitani and Nicholas Tulp posited that cancer was contagious based on 
the observation that breast cancer was often present in members of the same 
household (“The history of cancer,” 2012). The eighteenth century saw a 
movement away from this view to one that was caused by environmental and 
physiological factors; it was not until Virchow’s invention of the microscope in 
nineteenth century that physicians and scientists were able to truly examine and 
understand the damage caused by cancer in the human body (“The history of 
cancer,”  2012). Today cancer is one of the leading causes of mortality in the 
United States, second only to cardiac disease and responsible for the deaths of 
nearly 600,000 people annually (CDC.gov, 2010). Given its widespread 
prevalence and high rate of mortality, a tremendous effort has been made to find 
a cure for this disease. In 2012, over 1.3 billion dollars was spent on lung, 
prostate, breast, and colorectal cancer alone (cancer.gov, 2012). As our 
understanding of cancer at a cellular level has increased, new targets for 
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possible cancer treatment have arisen. One of these is the tumor-suppressor 
gene p53. 
 B. p53 
 The p53 tumor-suppressor protein is the subject of an incredible amount 
of research because of the role it plays in many different forms of malignant 
neoplasms. So frequently are mutations in the p53 protein seen that Bert 
Vogelstein, M.D., observes “it seems nearly impossible for a normal cell to 
become a cancer cell unless is inactivates the p53 network” (Vogelstein, 2010). 
Though originally believed to be an oncogene given its elevated levels in tumor 
cells (Vuong et al., 2012), landmark research by Baker and colleagues in the late 
1980s showed p53 served a much different function (Baker et al., 1989). Prior 
research showed that over 75% of colorectal carcinomas demonstrated allelic 
deletions on the short arm of chromosome 17, seen in Figure 1 below; 
furthermore, these deletions were frequently late events corresponding to the 
transition of a benign adenoma to a malignant carcinoma (Vogelstein et al., 
1988); Baker and colleagues set out to identify the common region of deletion in 
these carcinomas, eventually finding that the region coded for p53. Further study 
showed that malignant tumors containing an allelic deletion of p53 allele also 
contained a mutant form of the p53 gene on the remaining allele (Baker et al., 
1989). Corresponding data suggested the mutations led to a loss of tumor 
suppressor function of the p53 protein (Baker et al., 1989). For the first time, the 
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p53 gene was shown to be a tumor suppressor gene, not an oncogene, and in 
the case of colorectal cancer its loss of function appeared to play a decisive role 
in the progression and growth of the tumor. 
 
Figure 1. Map of the common region of deletions of the short arm of 
chromosome 17. These deletions are present in a majority of colorectal 
cancers, with 20 markers indicated. Eight separate tumors are shown, with 
hybridization results given at the far right. Numbers at the bottom identify 
patients. A loss of one parental allele is denoted with a completely filled circle, 
while retention of both parental alleles is denoted by a crosshatched circle. An 
empty circle denotes the marker was not informative. As shown in the 
hybridization result, in all tumors the region between markers YNZ22.1 and 
EW505 was deleted, denoting mutations of the p53 encoding region (Figure 
taken from Baker et al., 1989). 
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The discovery made by Baker and colleagues caused a fundamental shift in the 
view of p53 and lead to a great deal of research examining its anti-tumorigenic 
properties. 
  1. Structure of p53  
 p53 plays several highly important roles in normal cells, ranging from its 
regulation of cellular metabolism to its best known function as a tumor 
suppressor protein; p53 also participates in the transcriptional control of 
angiogenesis, cell migration, autophagy, stem cell renewal, and innate immunity 
(Wachter et al., 2013). The structure of normal wild-type p53 (wt-p53) contains 
three distinct regions as seen in Figure 2 below: the N-terminus transactivation 
domain, central binding domain, and C-terminus tetramerization domain 
(Mirzayans et al., 2012). The central binding domain of p53 is highly-specific to 
particular sequences of DNA. Upon binding to the gene in question, the 
transactivation domain of p53 transcribes downstream proteins which lead the 
cell senescence, cell cycle arrest, or apoptosis depending on the nature and 
extent of DNA damage or cellular stress (Wachter et al., 2013). It is the specificity 
of p53 transactivation activity that allows it to efficiently maintain genomic 
integrity in the cell (Ozaki et al., 2013). The tetramerization domain allows p53 to 
form dimers, optimizing the activity of p53 (Devine and Dai, 2013). Activation of 
p53 is achieved primarily through post-translational modifications in response to 
cell stress or DNA damage (Gostissa et al., 2012). 
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Figure 2. Basic structure of p53 protein. Shown are the three basic regions of 
the p53 protein: the N-terminus transactivation domain, central binding domain, 
and C-terminus Tetramerization domain. Also shown are common sites of post-
translational modification: circles represent sites of Ser/Thr phosphorylation, 
rectangles represent acetylation sites, and the hexagon represents a 
SUMOylation site. The box below shows several proteins that phosphorylate p53 
and the amino acids they target, while the box above the central binding domain 
shows the distribution of point mutations of p53 in human cancers (Figure taken 
from Mirzayans et al. 2012).  
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  2. Regulation of p53 
 Research has shown that “levels of p53 protein are extremely low in 
normal conditions, but p53 becomes stabilized and activated by a variety of 
posttranslational modifications in cells subjected to different types of DNA 
damage as well as upon overexpression of oncogenes” (Gostissa et al., 2012). 
Given the numerous and complex actions of p53, it is clear that careful regulation 
inside the cell is necessary to avoid unwanted activation. p53 protein is 
constitutively present and held at low levels in the cell and transported between 
the cytoplasm and nucleus in a manner dependent on the stage of the cell cycle, 
localizing in the cytoplasm during G1, nucleus during the G1 to S transition, and 
back to the cytoplasm after the beginning of S phase (Vuong et al., 2012). The 
major regulator protein responsible for holding p53 at low levels is Murine Double 
Minute 2 (MDM2, HDM2 in humans), via a negative feedback loop: as levels of 
p53 rise it increases the transcription of MDM2. MDM2, the structure of which 
can be seen in Figure 3 below, inhibits p53 in several ways including binding to 
its transactivation domain, targeting p53 for ubiquination or inhibiting acetylation 
of p53 by shuttling it to the cytoplasm (Balint and Vousden, 2001).  
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Figure 3. Structure of MDM2. Includes the nuclear localization signal (NLS), 
nuclear export signal (NES) and nucleolar localization signal (NoLS) (Figure 
taken from Balint and Vousden, 2001). 
 
Prior research has shown that in the absences of MDM2, p53 levels increase in 
an unrestrained manner and leads to inhibition of the normal growth and 
development of the cell (Balint and Vousden, 2001), illustrating its role in p53 
regulation. Acting as an ubiquitin E3 ligase, MDM2 marks the protein for 
proteasomal degradation via the 26S proteasome, avoiding an accumulating of 
excess levels of p53 in the cytosol by facilitating its turnover (Koom et al., 2012). 
Similar to MDM2, a second protein, MDMX, functions in much the same way and 
works to regulate p53 (Jhang et al., 2013). MDMX is an MDM2 homolog and 
often partners in binding with MDM2, increasing its efficacy in regulating p53 
(Divine and Dai 2013). 
  3. Activation of p53  
 In response to cell stress or DNA damage, p53 is activated and its half-life 
in the cell increases, stabilizing levels in the cell (Liang et al., 2013). Specifically 
in regards to cancer, if there is an overexpression of oncogenes such as c-Myc 
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or Ras, the Arf (alternative reading frame) of the INK4A locus will bind to the 
central binding domain of p53, blocking ubiquination by MDM2 and avoiding the 
proteasomal degradation of p53 (Devine and Dai, 2013). Arf can also act to 
sequester MDM2 in the nucleus of the cell, inhibiting it from binding to and 
regulating p53. (Devine and Dai, 2013). Furthermore, phosphorylation of both 
p53 and MDM2 by kinases blocks the protein-protein interaction between the two 
and allows for the stabilization of p53 (Balint and Vousden, 2001). In addition to 
these forms of regulation of p53 there are several co-activators that activate or 
modify p53 in the cell (Balint and Vousden, 2001). For example, in tumor cells 
Myc, an oncogenic transcription factor, induces the phosphorylation of p53, 
preventing it from binding to its negative regulator MDM2, and allowing it to 
mediate the mitochondrial-apoptotic pathway, thus destroying the tumor cell 
(Nieminen et al., 2012). A summary of the regulation and functions of p53 in the 
cell can be seen in Figure 4 below. 
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Figure 4. An overview of p53 function and regulation. p53 is normally 
regulated by several proteins including MDM2, Yyl and others that lead to its 
ubiquination and subsequent degradation. However, in response to stress, p53 
levels stabilize and it goes on to affect the transcription of numerous downstream 
products involved in regulating the cell cycle and apoptosis (Figure taken from 
Vuong et al., 2012). 
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  4. Functions of p53 in the cell 
 The roles of p53 are incredibly diverse and important to normal cellular 
function. p53 is involved in DNA repair, angiogenesis in the vascular system, cell 
migration, cell metabolism, stem cell renewal, and embryogenesis; it is best 
known, however, for the multiple functions it performs which aid in the blocking of 
both the initiation and progression of tumor growth within the cell (Wachter et al., 
2013). For the purposes of this review only four areas of p53 activity will be 
discussed as they are primary targets of p53-related research in regards to 
cancer therapy. Topics to be discussed will include the major anti-tumorigenic 
functions of p53 (seen in Figure 5 below) including its regulation of the cell cycle, 
cell senescence and apoptosis, as well as its regulation of cell metabolism and 
energy use.
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Figure 5. The anti-tumorigenic functions of p53. This figure shows the major 
functions of p53 in response to DNA damage or oncogenic growth. Based on the 
extent of the damage, p53 will induce cell cycle arrest and direct the cell to one of 
three options: senescence, DNA repair, or apoptosis. Above is shown the basic 
regulation of p53, a feedback loop with MDM2 and the Arf (Figure taken from 
Essmann and Schulze-Ostoff, 2010). 
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   a. p53 regulation of the cell cycle 
 One of the primary functions of p53 activity is to induce cell cycle arrest in 
a cell that has experienced stress or has accumulated mutations in its genome 
that need repair. To avoid replication of these mutations, stabilized levels of p53 
induce the transcription of a cyclin-dependent kinase inhibitor, known as factor 
p21, which is able to induce both G1 and G2 cell-cycle arrests as seen in Figure 
6 below (Balint and Vousden, 2001).  p21 acts by blocking the CD4/cyclin D 
complex; the CD4/cyclin D complex normally phosphorylates pRb 
(retinoblastoma protein), inducing the transcription factor E2F1 to trigger the 
progression from G1 to S (Vuong et al., 2012).  In regards to cancer therapy, it 
has been shown that the ability of p53 to arrest the cell cycle in the G1 phase 
promotes radiosensitivity to fractionated radiation in certain lung cancers, thereby 
causing a much better response to radiation treatment (Perez et al., 2013). p21 
can also arrest the cell cycle in the S phase by inhibiting PCNA (proliferating cell 
nuclear antigen) (Vuong et al., 2012).  
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Figure 6. The role of p53 in regulating cell cycle arrest. Through the 
transactivation of downstream targets such as p21 and Gadd45, p53 can induce 
ell cycle arrest at both the G1/S and G2/M checkpoints (Figure taken from 
Denaro et al., 2011). 
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   b. p53 regulation of cell senescence  
 p53 induces cell senescence, in response to an accumulation of genomic 
mutations, DNA damage, or over-expression of oncogenes (Vuong et al., 2012). 
Its mode of action is, like its regulation of the cell cycle, to transactivate 
downstream targets such as p21. It is now widely accepted that p21 plays an 
important regulatory role in several types of cell senescence, such as stress-
induced premature senescence (SIPS) and replicative senescence (Mirzayans et 
al., 2012). Its various roles in senescence can be seen in Figure 7 below. 
 
Figure 7. The various roles of p53-induced p21 in the cell. p21 positively 
regulate cell senescence genes, p53 and ATM. It inhibits cell-cycle progression 
through its interaction with cyclins/CDK complexes and PCNA. It has shown anti-
apoptotic effects through its interaction with ASK-1 and Capsase-3 (Figure taken 
from Mirzayans et al,. 2012). 
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   c. p53 regulation of apoptosis 
 In cases where the DNA damage is beyond repair or severe stress has 
completely compromised the cell, p53 will induce apoptosis, programmed cell 
death, in order to protect genomic integrity in the organism and avoid neoplastic 
growth (Balint and Vousden, 2001). The mode of action of p53, as in its other 
regulatory roles, is to transactivate downstream targets which will exert the 
desired effect, which can be seen in Figure 8 below. In activating target genes 
such as Bax, Noxa and PUMA, and by inhibiting anti-apoptotic genes such as 
bcl-2 (which suppresses the glutamine starvation mediated apoptotic pathway 
and inhibits the pro-apoptotic Bax), p53 induces cell apoptosis (Nieminen et al., 
2012, Wachter et al., 2013). These downstream targets of p53 typically operate 
by destabilizing the mitochondrial membrane potential and the release of 
cytochrome C, thus activating the Apaf-1/caspase-9 apoptotic cascade leading to 
the directed destruction of the cell (Balint and Vousden, 2001). It is via apoptosis 
that p53 primarily exerts its anti-tumorigenic effect, halting progression and even 
causing regression of the cancerous tumor (Gostissa et al., 2012). However, 
research has shown that p53 also displays anti-apoptotic properties, illustrating 
its complex roles in programmed cell death (Wachter et al., 2013). 
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Figure 8. Downstream target genes of p53 that induce apoptosis. Events in 
apoptosis are shown in the center pathway and include disruption of the 
mitochondrial membrane potential (mitochondria ΔΨ) followed by cytochrome C 
release and activation of caspases. The left cascade shows the anti-apoptotic 
actions of p53 by transactivating IGF-BP3 which inhibits IGF, in turn inhibiting 
apoptosis (Figure taken from Balint and Vousden, 2001).  
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   d. p53 regulation of cell metabolism 
 Recent research has shown p53 an important regulator of a cells energy 
metabolism, playing a role in oxidative phosphorylation, glycolysis, glutamine 
metabolism, lipid metabolism, and the antioxidant defense of the cell as shown in 
Figure 9 below (Liang et al., 2013). In 1926, Otto Warburg first characterized 
what became known as the Warburg effect, describing how a cancer cell 
primarily meets its energy needs from glycolysis as opposed to oxidative 
phosphorylation (Liang et al., 2013). Given the relative inefficiency of glycolysis 
when compared to oxidative phosphorylation, the tumor cell must 
commensurately increase its uptake of glucose to compensate, providing the 
basis for many diagnostic tests looking for cancerous tumors (Liang et al., 2013). 
In the normal cell, p53 acts to downregulate the glycolytic and pentose 
phosphate pathways while simultaneously upregulating oxidative phosphorylation 
in the mitochondria, directing the cell to primarily use oxidative phosphorylation in 
for its energy needs (Feng and Levine, 2010). In tumor cells, AMP-activated 
protein kinase (AMPK) monitors the energy status of the cell by monitoring the 
ratio of ATP to AMP/ADP. When this ratio falls due to a lack of glucose, AMPK 
phosphorylates and activates p53, which in turn induces apoptosis in the tumor 
cell (Nieminen et al., 2012). This regulatory function is often lost with the deletion 
or inactivation of p53 in many tumor cells, allowing the tumor cell to meet its high 
energy needs and grow uncontrollably. p53 function in energy metabolism has 
thus been established as a potential target for cancer therapy. 
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Figure 9. The many roles of p53 in regulating cellular energy metabolism. 
p53 functions in the regulation of processes such as glycolysis, oxidative 
phosphorylation, fatty acid oxidation and glutaminolysis. p53 induces the 
transcription SCO2, AIF, p53R2 and mtDNA to stabilize the mitochondrial 
membrane and promote the use of oxidative phosphorylation in the cell. At the 
same time, p53 represses the transcription of GLUT 1 and 4 and inhibits GLUT 3 
to reduce the uptake of glucose into the cell and decrease glycolysis (Figure 
taken from Liang et al., 2013). 
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   e. p53 role in antioxidant defense  
 p53 also plays an important role in the regulation of antioxidant defense in 
the cell. Oxidative stress and the accumulation of reactive oxygen species (ROS) 
is a source of DNA damage and often plays a role in the genesis of tumors in 
humans (Liang et al., 2013).  ROS are generated primarily by mitochondrial 
oxidative phosphorylation, a process p53 normally promotes in the cell while 
inhibiting glycolysis. In order to avoid the buildup of ROS, p53 transactivates 
several antioxidant genes including TIGAR, ALDH4 and sestrins1/2 which act to 
lower ROS levels in a variety of ways (Liang et al., 2013). p53 antioxidant effects 
can be seen in Figure 10 below, in response to low oxidative stress. In response 
to high levels of oxidative stress in the cell which produces DNA damage or 
mutations, p53 induces a pro-oxidant response that induces the increase of ROS 
levels in the cell (Liang et al., 2013). These increased levels of ROS in turn 
further activate p53, activating its anti-tumorigenic function in the cell and leading 
to cell senescence or apoptosis, as can be seen in Figure 10 below (Liang et al., 
2013).  
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Figure 10. p53 regulation of ROS and oxidative stress in the cell. In 
response to low levels of oxidative stress p53 transactivates antioxidant genes to 
lower ROS levels and avoid DNA damage or mutation. In response to high levels 
of oxidative stress p53 transactivates pro-oxidant genes which increase ROS 
species, leading to increased p53 activation. Increased p53 activity will 
eventually lead to apoptosis or cell senescence, thus avoiding tumorigenesis in 
the organism (Figure taken from Liang et al., 2013). 
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 C. Cancer treatment strategies utilizing p53 
 Animal models have consistently shown that p53 activation in tumors halts 
tumor progression and can be curative, even in later stages of cancer (Martins et 
al., 2006). This discovery has led to a considerable amount of research in search 
of a viable method for utilizing p53 in the treatment of cancer, and to date several 
strategies have been developed with varying success. The following sections will 
give an overview of different therapeutic approaches to treat cancer by 
reactivating p53 function. 
  1. Small molecules 
 A variety of small peptides have been developed with the intent of re-
activating p53 function when it has been lost in tumor cells. There are several 
different causes of p53 inactivation in cancer; commonly, allelic mutations or 
deletions of the p53 gene have removed its regulatory functions in the cell. Even 
in the event that wild-type p53 can be properly transcribed from one normal 
allele, it will incorporate mutant-type p53, transcribed from the mutated allele, 
during oligomerization and thus dampen any response to DNA damage or 
mutations that occur (Liu et al., 2000).  In this condition, the concentration of wild-
type p53 needs to be higher than endogenous mutant p53 to overcoming its 
dampening effect (Chan et al., 2004). In many tumors, however, the inactivating 
of p53 is not caused by a p53 mutation or deletion, but by an overexpression of 
MDM2, which acts to inactivate p53 and induce its proteasomal degradation, thus 
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removing p53 function in the cell (Balint, 2001). Small molecules have been 
developed targeting these causes of p53 inactivation. 
   a. MDM2/MDMX inhibitors 
 A common dysfunction in the p53 signaling system found in various 
cancer is the inactivation of p53 due to an upregulation of MDM2 or MDMX, the 
primary negative regulator of p53 (Devine and Dai, 2013). When p53 binds to a 
p53 responsive element in its gene, MDM2 transcription is activated and MDM2 
binds to the N-terminal domain of p53, inactivating it (Saha at al., 2013). This is 
purposed to avoid an unregulated p53 response in the cell. However, in cancer 
MDM2 can be constitutively activated, thus entirely removing the ability of p53 
levels to stabilize in response to DNA damage or oncogenic activation; the loss 
of p53 response allows for accumulation of genetic mutations and progression of 
the tumor (Essmann and Schulze-Ostoff, 2010). Compounds such as Nutlins, 
benzodiazepinediones and sulfonamides directly inhibit MDM2 from binding to 
p53, avoiding proteasomal degradation of p53 and allowing its levels to stabilize 
in the cell (Ozaki et al., 2013).  
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Figure 11. Strategies for inducing apoptosis with Nutlins. Cells with wt-p53 
can be induced to undergo apoptosis via p53 transcription-dependent or 
independent pathways. Nutlin can induce in apoptosis in mutant-p53 expressing 
cells via p53 or p73, but only to a partial extent (Figure taken from Saha et al., 
2013). 
 
Research has shown that treatment of various hematological malignancies, in 
which overexpression of MDM2 is common, with Nutlins alone reproduces the 
apoptotic and cytotoxic response in cells that is expected with wt-p53 as seen in 
Figure 11 above (Saha et al., 2013). Another peptide, RITA, directly interacts 
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with p53, causing a conformational shift that blocks the MDM2-p53 interaction, 
producing a similar effect to Nutlins (Essmann and Schulze-Osthoff, 2010). 
While promising, the one major shortcoming of small molecules such as Nutlins 
or RITA is their inability to reactivate mutant-type p53 in tumor cells where p53 
has been mutated of deleted (Saha et al., 2013).  
   b. Reactivation of wild-type function 
 Several small molecules have been designed to reactivate some wild-type 
function of p53, including PRIMA-1 and MIRA-1. Both PRIMA-1 and MIRA-1 
reconstitute wild-type function of mutant p53 in cancer cells by refolding the 
unfolded protein (Ozaki et al., 2013). This process is selective, leaving normal 
cells with wt-p53 unaffected (Ozaki et al., 2013). Their effect can be seen in 
Figure 12 below. 
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Figure 12. Strategies for inducing apoptosis using PRIMA-1 or MIRA-1. 
PRIMA-1 can induce apoptosis in p53 mutant cells. In certain cancer types, 
PRIMA-1 may induce apoptosis regardless of p53 status (shown in center 
cascade). In certain cancers, MIRA-1 has been shown to induce apoptosis 
regardless of cell type, though it primarily acts to reactivate mutant-type p53 
(Figure taken from Saha et al., 2013). 
 
As opposed to MDM2 inhibitors, however, there is little evidence to show PRIMA-
1 and MIRA-1 have any effect on cancer cells where p53 has been inactivated 
for reasons other than a mutation (in certain hematological cancers this has been 
observed regardless of p53 status) (Essmann and Schulze-Osthoff, 2010).  
   c. Inhibiting the proteasome  
 An additional target of small molecules is the proteasome. The 
proteasome functions to degrade many cyclical molecules in the cell to allow cell 
cycle progression; in an continuously proliferating cell like a tumor cell, the 
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proteasome must work overtime in order to degrade tumor suppressor proteins 
like p53 (Shen et al., 2013). Small molecules have been developed which inhibit 
both the 20S and 19S proteasomes. Compounds such as Bortezomib and 
peptide boronates have been developed to inhibit the 20S proteasome, while b-
AP15 inhibits the 19S proteasome (Shen et al., 2013). All three inhibitors cause 
stabilization of p53 levels in cells expressing the wild-type form, restoring p53 
function and leading to apoptosis of tumor cells (Shen et al., 2013). The 
shortcoming of proteasome inhibitors, like MDM2 inhibitors, is their therapeutic 
potential is limited to cells that express wild-type p53 and does not extend to cells 
with p53 mutations or deletions. 
 In short, there are several promising small molecule treatments for cancer, 
including some like Nutlins and PRIMA-1 that have reached clinical trials, 
however they are very specific to certain p53 deficiencies and therefore are 
limited in potential. 
  2. Gene therapy 
 Research in animal models has clearly shown that transfection of p53 into 
tumor cells with p53 mutations or deletions restores p53 function and leads to a 
halt of tumor progression and often tumor cell apoptosis (Lane et al., 2010). 
Other research has also shown that the presence of wild-type p53 increases the 
sensitivity of tumor cells to fractionated radiation, promoting the anti-tumorigenic 
effects of radiation therapy (Perez et al., 2013). Given the frequency of mutations 
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or deletions of p53 in human cancer (approximately 50% of human cancers as 
stated earlier), the goal of reactivating p53 in tumor cells using gene therapy is 
an emerging field full of potential in cancer therapy. Gene therapy is the transfer 
or insertion of a desired foreign gene into the genome of a cancer cell, with the 
hope that activation and replication of the gene will destruction of the tumor cells, 
as seen in Figure 13 below (Cross and Burmester, 2006). 
 
Figure 13. Basic diagram of gene therapy (Figure taken from Cross and 
Burmester, 2006) 
 
Many different gene types, including suicide genes and antiangiogenesis genes, 
have been proposed as viable options; given the well-established anti-
tumorigenic functions of p53, current research is exploring the possibility of 
inserting this gene into cancer cell as a therapeutic treatment. At question is the 
most efficient vector of introducing p53, several of which will be discussed below. 
   a. Retroviral vector 
 One vector that has been used in gene therapy is that of a retrovirus. 
Retroviruses carry a diploid RNA genome, within a viral capsid, that is integrated 
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into a host cells chromosome upon entry into the cell (Lim, 2012). Unlike many 
other vectors used in gene therapy, retroviruses have the capacity to be 
expressed in the host cell genome for long periods of time given the stability of 
their integration (Lim, 2012). Retroviruses were first used to introduce p53 into 
tumor cells of patients with non-small cell lung cancer by Dr. Jack Roth in 1996; 
of nine patients for whom traditional treatment failed, three saw tumor regression 
and another three tumor stabilization (Roth et al., 1996). Importantly, apoptosis 
was the primary response seen when wild-type p53 was integrated into the tumor 
cell genome (Roth et al., 1996). Research has shown that the integration of a 
retroviruses genetic material is not random but targets parts of the genome near 
transcriptional start sites as well as CpG islands, which are rich in regulatory 
elements (Lim et al., 2010).  Despite the early success shown by Jack Roth in 
using retrovirus vectors, substantial research has shown that retroviruses often 
display oncogenic properties in humans when integrated into a host genome, 
itself causing cells to transform and become malignant (Essmann and Shulze-
Osthoff, 2011). The promoter and enhancer components of the retrovirus long-
terminal repeat (LTR), used by the virus to insert its genetic material, have the 
ability to activate host cell oncogenes, thus initiating tumorigenesis (Hacein-Bey-
Abina et al., 2003). The retrovirus’ propensity for inserting its genetic material 
near transcriptional start sites and CpG islands further exacerbates this 
oncogenicity (Lim, 2012).  Given the serious threat of oncogenesis when using 
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retroviral gene therapy, other vectors have been sought out and largely replaced 
retroviruses for gene cancer therapy. 
   b. Adenovirus vector 
 The most common vector used to introduce wild-type p53 into tumor cells 
is human adenovirus (Cross and Burmester, 2006). Adenoviruses are composed 
of a capsid shell typically containing double stranded DNA. Adenoviruses bind to 
and are taken up by a host cell where, once inside the cell, they inject their 
nucleic acid content into the host cell’s nucleus for reproduction (Scherer et al., 
2011). An early trial using adenoviral vectors for gene therapy led to devastating 
consequences, when in 1999 Jesse Geisinger was treated for ornithine 
transcarbamylase (OTC) deficiency (Stolberg, 1999). The treatment caused a 
massive immune response, leading to “multiple-organ system failure” and the 
patient’s death (Stolberg, 1999). To avoid these terrible side effects, today’s 
adenoviruses are engineered to lack certainly proteins necessary for replication 
(Lane et al., 2010). This replication deficiency allows for large scale GMP 
production of the desired gene product, such as wild-type p53, for a transient 
period of time without the mass immune response or oncogenic risk seen in 
retroviruses (Essmann and Shulze-Osthoff, 2011). Following is an overview of 
human adenovirus biology and function which will serve as an introduction to a 
discussion on the use of adenovirus vectors to introduce or reactivate p53 in 
clinical settings. 
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    i. Adenovirus biology 
 Adenoviruses must be engineered to deliver genes such as p53 to cancer 
cells. The most common form of adenovirus used is human adenovirus serotype 
5; human adenovirus serotype 5 is one of 51 adenoviruses in the Adenoviridae 
family that has been characterized by its ability to be neutralized by animal 
antisera (Beatty and Curiel, 2012). The serotypes in this family are further 
subcategorized into six different species based on factors such as oncogenicity 
and genomic structure (Davison et al., 2003).  
    ii. Adenovirus structure 
 The human adenovirus is a 36 kilodalton genome of double-stranded DNA 
(Nemerow et al., 2012), encapsulated in a non-enveloping icosahedral capsid 
(Beatty and Curiel, 2012). For many years the structure of the capsid itself 
proved difficult to elucidate, but with the help of X-ray crystallography and 
electron microscopy this difficulty has been overcome and we know have a much 
greater understanding of its structure and composition (Beatty and Curiel, 2012). 
The capsid is composed primarily of three different proteins, hexon, penton base 
and fiber, and each of these proteins has a specific role in the adenovirus and its 
function (Nemerow et al., 2012). Based on information gleaned from X-ray 
crystallography, it is now believed hexon provides the sites of contact between 
neighboring particles in the crystal lattice of the capsid, as well as with 
neighboring loops or cement proteins (Reddy et al., 2010). Data has shown that 
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the penton base protein serves to attach surface integrins, which act as receptors 
that mediate the internalization of the virus, to the capsids outer surface 
(Wickham et al., 1994). Finally, the primary role of fiber protein is as the site of 
cellular attachment (Zubieta et al., 2005). The structure of human adenovirus and 
the roles of its integral capsid proteins can be seen in Figures 14 and 15 below. 
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Figure 14. The capsid structure of human adenovirus. The capsid is 
composed primarily of the proteins hexon, penton base, and fiber which are 
labeled. Also labeled is a minor protein in the capsid structure, polypeptide IX, 
which has been hypothesized as a possible locus for targeted incorporation in 
addition to the three primary components. (Figure taken from Beatty and Curiel, 
2012) 
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Figure 15. Geometric representation of the human adenovirus. This 
representation shows the arrangement of hexon, penton base, and fiber proteins, 
including the icosahedral lattice of hexon trimmers in red, yellow and green, and 
the penton base subunits at the vertices of the capsid, shown in magenta. 
(Figure taken from Nemerow et al., 2012). 
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    iii. Mechanism of entry 
 In order for the adenovirus to deliver its contents into the target cell’s 
genome it must first enter the cell and reach the nucleus. The first step in the 
entry of an adenovirus is the attachment to its primary receptor on the cell 
surface (Beatty and Curiel, 2012).  The binding of an adenovirus to its receptor is 
carried out by fiber proteins on the capsid surface; depending on the subcategory 
of adenovirus being used, the receptor may vary but is most commonly the 
coxsackie and AD receptor (CAR) (Beatty and Curiel, 2012), a 46 kilodalton 
immunoglobulin that is normally found in the formation of tight junctions between 
cells (Coyne and Bergelson, 2006). Secondly, the adenovirus must then be 
internalized into the cell. Upon binding to the cell, surface integrins interact with 
the penton base of the adenovirus, inducing the cytoskeleton of the cell to alter 
itself and internalize the virus in a clathrin coated vesicle (Li et al., 1998). The 
virus is carried by this clathrin-coated vesicle to the endosome within the cell, 
from which it eventually escapes and is released into the cytoplasm (Meier et al., 
2002). Once in the cytoplasm, the virus must reach the nucleus. Recent research 
has shown that once in the cytoplasm, adenovirus recruits the motor protein 
dynein, which it uses to travel along microtubules towards the centrosome in the 
vicinity of the nucleus (Scherer et al., 2011). Once it has reached the nucleus, 
the virus binds to a nuclear pore complex (NPC) on the surface of the nuclear 
membrane and injects its contents into the nucleus (Scherer et al., 2011). The 
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mechanism of adenovirus binding to CAR, endocytosis, and movement to along 
microtubules to the nucleus can be seen in Figure 16 below. 
 
Figure 16. Mechanism of entry of an adenovirus. Adenovirus binds to CAR on 
the plasma membrane and is endocytosed by the host cell. After it is released 
form the endosome it then moves along microtubules, using dynein, until it 
reaches the nuclear membrane, at which point it injects its contents through a 
nuclear pore (Figure taken from Scherer et al., 2011). 
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II. Evaluation of Ad-p53 in cancer treatment 
 A. Non-small cell lung cancer 
 After research by Dr. Jack Roth showed that retroviral introduction of wild-
type p53 caused tumor apoptosis and regression in non-small cell lung cancer 
(NSCLC) (Roth et al., 1996), trials using adenovirus-mediated transfer of wild-
type p53 were begun in order to avoid the negative oncogenic effects of 
retroviruses. Research using animal models showed that adenovirus carrying 
p53 (Ad-p53) maintained the anti-tumor properties seen with retroviral vectors 
(Swisher et al., 1999). In 1999 a phase 1 clinical trial was conducted on 28 
patients whose NSCLC had progressed in spite of conventional therapeutic 
approaches by injecting Ad-p53 monthly for a total of up to 6 treatments (Swisher 
et al., 1999). A range of doses was used to evaluate if any p53 response was 
dose-dependent. Results showed adenovirus vector DNA in 86% of patients with 
evaluable biopsy specimens, supporting the efficacy of adenovirus as a vector for 
gene therapy in cancer treatment, though p53 expression was seen more 
frequently in patients receiving higher doses, indicating a dose-dependency 
(Swisher et al., 1999). Most importantly, of the 25 evaluable patients, tumor 
stabilization was seen in 16 patients and tumor progression seen in only 7 
patients (the final 2 patients showed only partial responses), all with minimal to 
no adverse effects accompanying treatment (Swisher et al., 1999). These results, 
which can be seen in Table 1 below, indicate that Ad-p53 is a viable treatment 
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option for NSCLC, even in advanced stages, with minimal negative effects seen 
in therapeutic approaches. 
Table 1. Evaluation of the efficacy of Ad-p53 treatment of NSCLC  
 
 (Table taken from Swisher et al., 1999) 
 
Another trial performed at the West China Hospital of Sichuan University 
combined a replication deficient adenovirus expressing wild-type p53 (rAd-p53), 
known as Gendicine, with bronchial arterial infusion. Gendicine in combination 
with chemotherapy and radiotherapy has previously been shown to significantly 
improve therapeutic effects in head and neck cancer (Guan et al., 2009). Two 
groups, one receiving the combination of treatments and the other receiving only 
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the bronchial arterial infusion, were examined; results showed a 47.3% response 
rate with the combination group, and a 38.4% response rate with the control 
group (Guan et al., 2009). The rAd-p53 lead to a slowed progression of the 
disease, however it did not produce better survival results (Guan et al., 2009). 
The results of this study can be seen in Table 2 below. 
Table 2. Evaluation of the efficacy of rAd-p53 in combination with bronchial 
arterial infusion in treating NSCLC. 
 
(Taken from Guan et al., 2009) 
Similar results were seen in a phase II clinical trial combining Ad-p53 with 
traditional chemotherapy for the treatment of NSCLC, in which a response rate of 
52% was seen in patients treated with the combination (Shuler et al., 2001). 
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However there was no statistical distinction between this group and the control 
group receiving only chemotherapy, in which a 48% response was seen, 
indicating there was no advantage to receiving Ad-p53 in treating NSCLC (Shuler 
et al., 2001). 
 After several studies, there is no consensus as to the efficacy of Ad-p53 
gene therapy for the treatment of NSCLC. Though adenovirus DNA, and in turn 
p53 messenger RNA, was consistently seen, this therapeutic approach did not 
consistently provide better outcomes when compared to traditional treatment. 
 B. Breast Cancer 
 Breast cancer is the most common cancer seen in women. Currently the 
primary mode of treatment is the use of cytotoxic chemotherapy, and response to 
this treatment is the most important prognostic indicator for long term outcomes 
(Cristofanilli et al., 2006). Several clinical studies have been or are currently 
being performed to evaluate the use of gene therapy, targeting several different 
genes commonly seen mutated in breast cancer (Takahashi et al., 2006). Given 
the high incidence of mutation of the p53 gene in breast cancer, a phase II 
clinical trial using adenovirus mediated p53 gene transfer was performed. The 
drug Advexin is a non-replicating adenovirus carrying the wild-type p53 gene and 
was given in combination with traditional chemotherapy to treat locally advanced 
breast cancer (LABC) (Cristofallini et al., 2006). In the13 patients treated with the 
combination treatment, none presented with a complete clinical response, 
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defined as the complete disappearance of the localized tumor; however, of the 
12 evaluable patients, all showed a partial clinical response representing a 50% 
reduction in tumor size, as can be seen in Table 3 below (Cristofallini et al., 
2006). 
Table 3. Evaluation of the efficacy of Ad-p53 treatment for locally advance 
breast cancer. (Taken from Cristofallini et al., 2006) 
 
Further research has shown that Ad-p53 treatment sensitizes breast cancer cells 
to adriamycin, a traditional chemotherapy treatment to which breast cancer tumor 
cells show a resistance (Qi et al., 2011). The effect of this loss of resistance led 
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to apoptosis of the tumor cells (Qi et al., 2011). Clinical trials using this treatment 
approach have yet to be performed. 
 Though the use of adenovirus-mediated p53 gene transfer to treat breast 
cancer is still in the early stages, initial results have been very positive. 
Specifically the combination of Ad-p53 and traditional chemotherapy seems to be 
very effective. Further research and clinical trials will be needed to fully evaluate 
this therapeutic approach, but the potential for breast cancer treatment appears 
high. 
 C. Gastric Cancer 
 Gastric cancer, the most common form of cancer in the digestive system, 
has been the subject of numerous studies involving adenovirus-mediated p53 
gene therapy. Early studies on four different gastric cancer cell lines showed that 
introduction of wild-type p53 to lines with mutated p53 led to tumor regression via 
apoptosis of tumor cells (Ohashi et al., 1999), while lines already expressing 
wild-type p53 did not show tumor regression (Ohashi et al., 1999). These early 
results indicated a great amount of promise for Ad-p53 treatment of gastric 
cancer. More recent research comparing the anti-tumor effects of Ad-p53 in 
combination with oxaliplatin, a common chemotherapeutic drug used in digestive 
cancer, showed significant synergistic effects between the two (Chen et al., 
2011). The study, the results of which can be seen below in Figure 17 below, 
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also confirmed that Ad-p53 treatment alone leads to gastric tumor regression, as 
shown prior (Chen et al., 2011). 
 
Figure 17. Efficacy of Ad-p53 in combination oxaliplatin in treating gastric 
cancer. Groups a, b, c, and d were treated with increasing doses of oxaliplatin, 
illustrating a dose dependency of oxaliplatin. Groups A, B, C, and D were treated 
with increasing doses of Ad-p53, also displaying a dose dependency. 
Importantly, the synergistic effects of combining Ad-p53 and oxaliplatin can be 
seen when comparing groups A, B, C, and D to groups E and F, which did not 
receive Ad-p53. (Figure taken from Chen et al., 2011) 
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The recombinant adenovirus Gendicine has also been used, in combination with 
the cytotoxic chemotherapy agent epirubicin hydrochloride, to treat gastric cancer 
in animal models both in vitro and in vivo (Xie et al., 2010). Much like the results 
seen when used in combination with oxliplatin, Gendicine not only led to tumor 
regression when used alone but displayed synergistic effects when combined 
with epirubicin hydrochloride (Xie et al., 2010). 
 Though no human trials have yet to be completed using Ad-p53 to treat 
gastric cancer, in vitro and in vivo studies have been extremely promising. Not 
only has traditional Ad-p53 therapy been effective, but recent strides have seen 
the development of an adenovirus which co-transduces p53 with RPL23 (Ad-
RLP23/p53), a gene that has been shown to protect wild-type p53 from MDM2 
inactivation (Zhang et al., 2013). The benefits of this co-transduction are 
tremendous. Unlike prior studies which saw a resistance to Ad-p53 treatment by 
cancer cell lines expressing wild-type p53 (Ohashi et al., 1999), Ad-RLP23/p53 
induced antitumor responses in both cell lines expressing mutant p53 and wild-
type p53, likely by rescuing wild-type p53 from the inactivating effects of MDM2 
overexpression (Zhang et al., 2013). This is an exciting breakthrough in gene 
therapy because it allows for a single drug to treat multiple genetic mutations that 
inactivate p53, increasing its efficacy in treating a broad range of patients. Multi-
gene targeting such as this may lead to new and more efficient therapeutic 
approaches in cancer treatment. 
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 D. Osteosarcoma 
 One of the most common bone cancers, osteosarcoma is another target of 
gene therapy using adenovirus-mediated p53 gene transfer. Current therapeutic 
approaches including surgery, radiation, and chemotherapy have proven 
insufficient in the treatment of osteosarcoma and the prognosis of this disease 
remains poor, making the need for a novel approach such as gene therapy 
evident (Ternovoi et al., 2006). The use of Ad-p53 has been shown to exhibit 
anti-tumor effects in canine osteosarcoma grafts on nude mice via apoptosis of 
the tumor cells (Kanaya et al., 2011). Research has also shown that while Ad-
p53 induces apoptosis in human osteosarcoma cell lines alone, it also enhances 
the sensitivity of osteosarcoma cells to cisplatin and doxorubicin, traditional 
chemotherapeutic drugs (Oshima et al., 2007, Ternovoi et al., 2006). However, it 
has also been noted that certain osteosarcoma cell lines are resistant to wild-
type p53 introduction, likely due to the inactivating effect of overexpressed MDM2 
(Hellwinkel et al., 2005). Despite this issue, Ad-p53 has proven itself a viable 
potential treatment for osteosarcoma, especially when given in combination with 
traditional chemotherapy, but further research must be undertaken to better 
understand the effect of Ad-p53 in osteosarcoma cells before it can be taken to 
the clinical trial stage. 
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 E. Hepatocellular carcinoma 
 Hepatocellular carcinoma is one of the most common cancers in the 
world, especially in regions of the world where infection with hepatitis is at 
epidemic levels (Habib et al., 2002). Early research examining the efficacy of 
adenovirus-mediated p53 gene therapy, while well-tolerated and with minimal 
side effects, showed a very minimal anti-tumor effect in most subjects (Habib et 
al., 2002), leading researchers to speculate that perhaps a more effective vector 
for was needed. Subsequent clinical trials, however, have shown that Ad-p53 in 
combination with traditional chemotherapeutic agents has been highly effective 
and led to cancer cell apoptosis and tumor regression (Koom et al., 2012, Guan 
et al., 2011). One clinical trial combining Ad-p53 with transcatheter hepatic 
arterial chemoembolization saw a success double that of the control group 
treated with hepatic arterial chemoembolization alone (Guan et al., 2011). 
Importantly, the survival rates of patients treated with the combination were 
significantly higher than those of the control group (Guan et al., 2011). A 
separate study illustrated a similar synergistic effect between Ad-p53 and 
radiotherapy in vivo using animal models, especially in tumor cells with low levels 
of MDM2 expression (Koom et al., 2012). Perhaps more importantly, this study 
also examined the use of an adenovirus carrying a modified p53 gene designed 
with the transactivation domain replaced with the herpes simplex virus vp16; this 
modified p53 gene, seen in Figure 18, no longer possesses the MDM2 binding 
site and avoids the negative feedback loop of MDM2, leading to a high efficacy in 
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treating hepatocellular carcinoma in tumor cells with high levels of MDM2 being 
expressed (Koom et al., 2012). 
 
Figure 18. Map of adenoviral vectors used in p53 gene therapy. Both Ad-p53 
and the recombinant adenovirus Ad-p53vp are illustrated. The E1 region in both 
is deleted, making the virus replication-deficient. In the Ad-p53vp, the 
transactivation domain has been replaced with the herpes simplex virus vp16, 
freeing p53 from MDM2 inactivation. (Figure taken from Koom et al., 2012) 
 
 
Recombinant adenoviruses, similar to Gendicine (originally authorized in China 
for the treatment of head and neck cancer) have been evaluated as a treatment 
for hepatocellular carcinoma as well. Two trials used recombinant adenoviruses 
in combination with two different traditional treatments. When combined with 
fractionated stereotactic radiotherapy, the treatment led to a higher response rate 
than with radiotherapy alone, as well as a better survival rate (Yang et al., 2010). 
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Treatment in combination with the chemotherapy agent 5-fluorouracil and 
following transcatheter arterial chemoembolization led to higher responses to 
treatment as well as better survival rates (Tian et al., 2009). 
 In treating hepatocellular carcinoma, Ad-p53 in combination with 
traditional treatments such as chemotherapy or radiation therapy has shown high 
efficacy and minimal adverse effects, following the pattern seen when treating 
other forms of cancer. The use of a modified adenovirus like Ad-p53vp to avoid 
MDM2 inhibition is another positive step towards the development of a virus that 
may target a wide range of p53 mutations or causes of inactivation, thus 
potentially treating a wide array of cancers. 
 F. Head and neck cancer 
 Some of the earliest attempts to use adenovirus mediated p53 gene 
therapy was for head and neck cancers. After seeing tumor regression in animal 
xenografts models using Ad-p53, a clinical trial was performed to evaluate the 
efficacy of Ad-p53 in human subjects with head and neck squamous cell 
carcinoma, in which traditional treatments caused high rates of morbidity 
(Clayman et al., 1998). Results were positive, with no adverse side effects and 
tumor regression or stabilization in half of evaluable patients (Clayman et al., 
1998). A separate clinical trial evaluated the efficacy of SBN-1, a recombinant 
adenovirus carrying p53, in combination with traditional radiotherapy to treat 
head and neck squamous cell carcinoma. When compared to a control group 
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receiving radiotherapy alone, patients receiving the combination of treatments 
showed significantly higher rates of tumor regression with no toxic side effects 
(Zhang et al., 2003). These findings are consistent with results from the use of 
Ad-p53 in combination with traditional chemotherapy or radiotherapy to treat 
many other cancer types, as discussed prior. 
  1. Oncolytic virotherapy 
 Another direction taken by researchers to treat head and neck cancer with 
adenovirus-mediated p53 is in the field of oncolytic virotherapy. Onyx-015 is an 
oncolytic virus that has been heavily researched as a potential treatment for head 
and neck cancer, as well as a variety of different cancers. Onyx-015 was 
developed with the E1B 55K gene deleted; this gene codes for a 55K protein that 
binds directly to and degrades p53, thus allowing the virus to replicate in the cell 
while avoiding the p53 induction and inhibition that would normally occur upon 
infection (McCormick, 2003).  The effectiveness of Onyx-015 comes from the fact 
that it selectively replicates in cells where p53 is mutated or inactivated, such as 
tumor cells, while being unable to inhibit p53 and avoid degradation in normal 
cells (McCormick, 2003). This allows for specific targeting of tumor cells while 
avoiding unwanted p53 activation in normal cells. A phase II clinical trial 
evaluated the combined treatment of Onyx-015 with the traditional 
chemotherapeutic agents cisplatin and 5-fluorouracil. The responses, described 
as “substantial” by the research team, saw 0% tumor progression in patients 
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responding to the combined treatment, while the control group had a tumor 
progression rate of 100% after 6 months (Khuri et al., 2000). A separate phase II 
clinical trial evaluating the efficacy of Onyx-015 alone to treat head and neck 
squamous cell carcinoma showed tumor regression or stabilization in 55% of 
patients receiving the standard treatment of intratumoral injection for 5 
consecutive days (Nemunaitis et al., 2001). This study also evaluated the 
administration of Onyx-015 in a fractionated manner (twice daily for two 
consecutive weeks) and saw a remarkable 72% tumor regression or stabilization, 
indicating that Onyx-015 infection is transient and its effects pronounced when 
given more frequently (Nemunaitis et al., 2001). Previous studies had shown that 
Onyx-015 induced apoptosis was highly selective to cancer cells (Nemunaitis et 
al., 2000), an observation seen in this trial. One possible shortcoming of Onyx-
015 that has been observed is its apparent inability to induce tumor necrosis of 
cancer cells that possess wild-type p53, as seen in Table 4 below (Nemunaitis et 
al., 2000), slightly limiting its efficacy in treating tumors with inactivated p53.  
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Table 4. Evaluation of the efficacy of Onyx-015 in the treatment of head and 
neck squamous cell carcinoma. (Taken from Nemunaitis et al., 2000) 
 
At the same time, the effectiveness of Onyx-015 in combination with traditional 
chemotherapy is extremely promising for the field of oncolytic virotherapy. 
Recent research has also illustrated that the effects of Onyx-015 are not solely 
due to its ability to selectively replicate in mutant p53 expressing cells but an 
overall stress response of the infected cell (Lane et al., 2013). Regardless, this 
approach holds great potential for cancer treatment.  
 The use of adenovirus-mediated p53 gene transfer has shown promising 
results for head and neck cancer. As in the treatment of other forms of cancer 
using this method, development is still progressing, with phase II and III clinical 
trials representing the furthest advancement. The use of oncolytic virotherapy 
with drugs such as Onyx-015 remains promising.  H101, a virus similar to Onyx-
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015, in combination with chemotherapy has been approved for treatment of 
certain cancers in China. This field continues to be developed (Lane et al., 2013). 
III. Conclusion, future aims 
 The search for a cure for cancer remains a top priority in the medical 
community. The pervasiveness of this disease throughout society and its 
devastating consequences continue to plague families across the world. 
Unfortunately, as our understanding of the disease has progressed, it has 
become apparent that there is not likely a “one-size-fits-all” cure. The complex 
molecular genetics behind cancer illustrate the wide range of mutations and 
molecular abnormalities that can lead to tumorigenesis. In combination with 
environmental and predisposing factors, the potential causes of cancer seem 
limitless and likely to continue increasing in tandem with our knowledge of the 
disease. Traditional treatments have given many patients a fighting chance but 
have still come woefully short of stemming the tide of cancer mortalities occurring 
each day. Furthermore, the toxic effects of traditional treatments like 
chemotherapy and radiotherapy often hinder more than help an already 
weakened patient; simultaneously killing cancer and patient. 
 The field of gene therapy has made great strides over the course of the 
past decade. As our understanding of the field of genetics has increased, 
researchers have been able to develop treatments that target cancer more 
directly while avoiding the systemically toxic effects often seen with more 
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traditional treatments like chemotherapy and radiotherapy. This factor alone 
gives much promise to gene therapy. Gene therapy targeting p53 reactivation, 
specifically, allows for the potential treatment of half of all cancer cases seen, a 
vast swathe of the disease. 
 Of the current possibilities for p53 reactivation being researched, the 
option displaying the greatest potential is using adenoviruses as a vector for p53 
introduction. While small molecule treatment options do show promise, their 
focus is too narrow. Nutlins and RITA, the two MDM2/MDMX inhibitors 
discussed, can be effective in wild-type 53 expressing where MDM2 
overexpression is inhibiting the normal p53 protein, however they exert no 
therapeutic effects in cells expressing a mutant p53 variant, a very common 
mutation in cancer. PRIMA-1 and MIRA-1, on the other hand, reactivate mutant 
p53 but have no effect in cells expression wild-type p53 and high levels of 
MDM2/MDMX. Small molecules inhibiting proteasomal degradation of p53, like 
Nutlins and RITA, are unable to exert therapeutic effects in cells expressing a 
mutated variant of p53. In order to have the greatest possible impact on cancers 
involving p53 inactivation, all three types of small molecules would need to be 
researched and developed further, an already expensive process compounded 
by the need for each separate drug. The flexibility of gene therapy seems to be a 
much better option given its ability to target all forms of p53 inactivation with one 
type of treatment. Of the two primary options for transmission of the p53 gene, 
adenoviruses and retroviruses, the oncogenicity of retroviruses is too great a risk 
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factor, especially when compared to the safety and overall lack of toxic effects 
seen from adenoviral vectors. 
 With the use of adenovirus as the best course for p53 introduction 
established, results from clinical trials suggest that the strategy of using 
adenovirus-mediated p53 gene therapy in combination with either chemotherapy 
or radiotherapy is currently the best course of treatment for cancers showing p53 
mutation or inactivation. In every study evaluated, the use of a combination 
treatment showed statistically greater efficacy, as measured by tumor regression 
or stabilization, than the traditional treatments alone. Furthermore, a cross-
comparison of studies evaluating combination treatments with studies evaluating 
the efficacy of Ad-p53 alone showed the combination largely led to a greater 
percentage of positive responses to treatment, suggesting a synergistic effect 
between the gene therapy and traditional cytotoxic therapy. The combination of 
treatments also permits for the reduction of the amount of traditional 
chemotherapy or radiotherapy given, allowing physicians to tailor treatment 
protocols based on a patient’s current health and ability to withstand the potential 
side effects of cytotoxic treatment. These combination treatments must progress 
beyond the clinical trial phase and be approved for clinical use so they may begin 
to improve outcomes for those suffering from cancer, even as further refining of 
gene therapy continues. 
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 The true future of cancer treatment lies in the development of recombinant 
adenoviruses carrying engineered p53. A slight shortcoming of normal Ad-p53 
has been its decreased efficacy when treating tumor cells already expressing 
wild-type p53 but overexpressing MDM2/MDMX. Because adenovirus-mediated 
p53 is translated to high titer, the resulting concentration is able to escape 
complete MDM2/MDMX inhibition, but not without a dampening effect on its 
ability to induce tumor regression or stabilization. The engineered Ad-p53vp, 
however, escaped this inhibition and displayed an equivalent efficacy in treating 
both mutant p53 expressing and wild-type p53/elevated MDM2 expressing 
cancer cells. Ad-RLP23/p53 was also able to escape MDM2/MDMX inhibition by 
co-transducing a second gene, RLP23, along with the p53 gene that protected 
p53 and allowing it to exert its full anti-tumor effects. Both engineered products 
enabled adenovirus-mediated p53 to maximize its anti-tumor potential regardless 
of the cause of p53 inactivation. And oncolytic viruses like Onyx-015 represent 
another, more refined step towards selectively targeting and destroying cancer 
cells, taking advantage of molecular interactions in p53 regulation to allow for 
viral reproduction only in tumor cells, avoiding any negative side effects in 
normal, wild-type p53 expressing cells. Engineered viruses such as these 
represent the future of cancer treatment, but currently a great deal more research 
is necessary to continue refining these treatments and maximizing their ability to 
treat a wide range of cancers. 
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